NCCN CNS Guidelines Updated to Include Taletrectinib for ROS1+ NSCLC

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Central Nervous System (CNS) Cancers to include taletrectinib (Ibtrozi) as a recommended systemic therapy option. The update, finalized on April 24, 2026, specifically designates the next-generation tyrosine kinase inhibitor (TKI) for use in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC) who present with brain metastases.^1,2

This inclusion follows the previous addition of taletrectinib to the NCCN Guidelines for NSCLC in June 2025, where it was categorized as a "Preferred Agent" for both treatment-naive and previously treated patients. The current expansion into the CNS guidelines highlights the clinical necessity of addressing intracranial disease, which remains a primary site of progression and mortality for patients harboring ROS1 rearrangements.

Clinical Efficacy and Intracranial Response

The NCCN recommendation is supported by data from the TRUST clinical program, including the TRUST-I (NCT04395677)³ and TRUST-II (NCT04919811)⁴ trials. Recent efficacy results presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 demonstrated significant blood-brain barrier penetrance and durable intracranial activity.¹

In patients who were TKI-naive, taletrectinib achieved an intracranial overall response rate (IC-ORR) of 76.5%. Among patients who had previously received TKI therapy—a population that often faces limited subsequent systemic options—the IC-ORR remained robust at 65.6%. These data suggest that taletrectinib may overcome some of the limitations observed with first-generation TKIs, which frequently fail to maintain therapeutic concentrations in the CNS or succumb to emergent resistance mutations.

Therapeutic Rationale in ROS1+ Disease

ROS1 rearrangements occur in approximately 2% of all NSCLC cases, typically affecting a younger patient demographic (median age of 50 years) and those with a limited smoking history. While rare, the disease is aggressive and possesses a high tropism for the central nervous system. Approximately 35% of patients with metastatic ROS1+ NSCLC have brain metastases at the time of initial diagnosis. Furthermore, the brain is the most common site of first progression, occurring in nearly 50% of patients receiving earlier-generation therapies.

The clinical profile of taletrectinib is characterized by high selectivity for the ROS1 kinase domain. Unlike some earlier inhibitors, taletrectinib was engineered to provide potent inhibition while maintaining a favorable neurologic safety profile, minimizing the off-target CNS toxicities sometimes associated with broader-spectrum inhibitors.

Regulatory and Trial Landscape

The FDA granted taletrectinib approval on June 11, 2025 for the treatment of adults with locally advanced or metastatic ROS1+ NSCLC.⁵ This approval was supported by its designations as a breakthrough therapy for both TKI-naive and TKI-pretreated cohorts.

The ongoing TRUST clinical program continues to evaluate the long-term utility of the agent across different disease stages. TRUST-III (NCT06564324)⁶ is a confirmatory phase 3 randomized study in China comparing taletrectinib against crizotinib (Xalkori) in TKI-naive patients. Additionally, the TRUST-IV trial (NCT07154706)⁷ is investigating the efficacy of taletrectinib in the adjuvant setting for patients with resected early-stage ROS1+ NSCLC, with a primary completion date estimated for 2030.

The NCCN update positions taletrectinib as one of the few targeted therapies recognized across both the NSCLC and CNS guidelines, reflecting a shift toward prioritizing agents with proven intracranial durability in the management of oncogene-driven lung cancers.¹

REFERENCES

1. Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers. News release. Nuvation Bio. April 27, 2026. Accessed April 27, 2026. https://tinyurl.com/3f37bvh2

2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Central Nervous System Cancers. Version 1.2026. Published April 24, 2026.

3. Li W, Xiong A, Yang N, et al. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. 2024 Aug 1;42(22):2660-2670. doi: 10.1200/JCO.24.00731. Epub 2024 Jun 1. PMID: 38822758; PMCID: PMC11272140.

4. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II). ClinicalTrials.gov. Updated January 7, 2026. Accessed April 27, 2026. https://clinicaltrials.gov/study/NCT04919811

5. FDA approves taletrectinib for ROS1-positive non-small cell lung cancer. News release. US FDA. June 11, 2025. Accessed April 27, 2026. https://tinyurl.com/4v5bkvfh

6. Pérol M, Li W, Pennell N, et al. Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST. J Clin Oncol 43, 1920-1929(2025). doi:10.1200/JCO-25-00275

7. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV). ClinicalTrials.gov. Updated April 14, 2026. Accessed April 27, 2026. https://clinicaltrials.gov/study/NCT07154706